4 Healthcare Stock Stories for a Tuesday Investment Checkup

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

GlaxoSmithKline (NYSE:GSK): Closing price $51.85

GlaxoSmithKline reports the FDA approval of its quadrivalent formulation of intramuscular Flulaval. Flulaval Quadrivalent has been cleared for the prevention of influenza caused by types A and B strains in adults and children aged 3 years and older. Flulaval Quadrivalent helps fight against two strains of influenza A and two strains of influenza B, thus giving it an advantage over the presently-available trivalent Flulaval version, which is only okayed for use in adults. The company expects the approval of Flulaval Quadrivalent to permit it to solidify its position in the market once it is made available in 2014.

Are these stocks a buy or sell? Let us help you decide. GSK-20130820

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business